Scientists are looking at ways to simplify Hepatitis C (HCV) treatment. This study is trying to find out if minimal, or fewer, tests during treatment for Hepatitis C have the same efficacy as current standard monitoring tests (according to recent data and current practices for standard HCV monitoring). This study will include people who are infected with HCV without advanced liver disease, regardless of HIV co-infection (both with or without HIV infection will be accepted; either on antiretroviral therapy or not yet having started antiretroviral therapy; and never have used treatment for Hepatitis C. Participants will receive the fixed-dose combination of Sofosbuvir/Velpatasvir (SOF/VEL) for 12 weeks.
Participants will received a fixed-dose combination of Sofosbuvir/Velpatasvir (SOF/VEL) single-tablet regiment for 12 weeks. This will be followed by follow-up visits at weeks 24, 48, and 72.